Preview Citation


Clark, P. E.1MD, Spiess, P. E.2MD, MS, Agarwal, N.3MD, Bangs, R.4MBA, Boorjian, S. A.5MD, Buyyounouski, M. K.6MD, MS, Efstathiou, J. A.7MD, DPhil, Flaig, T. W.8MD, Friedlander, T.9MD, Greenberg, R. E.10MD, Guru, K. A.11MD, Hahn, N.12MD, Herr, H. W.13MD, Hoimes, C.14MD, Inman, B. A.15MD, MSc, Kader, A.16MD, PhD, Kibel, A. S.17MD, Kuzel, T. M.18MD, Lele, S. M.19MD, Meeks, J. J.18MD, PhD, Michalski, J.20MD, MBA, Montgomery, J. S.21MD, MHSA, Pagliaro, L. C.5MD, Pal, S. K.22MD, Patterson, A.23MD, Petrylak, D.24MD, Plimack, E. R.10MD, MS, Pohar, K. S.25MD, Porter, M. P.26MD, MS, Sexton, W. J.2MD, Siefker-Radtke, A. O.27MD, Sonpavde, G.28MD, Tward, J.3MD, PhD, Wile, G.1MD, Dwyer, M. A.29MS, CGC, & Smith, C.29PhD, MT(ASCP). (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016, Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 14(10), 1213-1224. Retrieved May 24, 2019, from